Precision oncology in practice – testing through to treatment in lung and prostate cancer

Fernando Lopez-Rios is the Chief of the Molecular Diagnostics Service at Hospital Universitario 12 de Octubre (Madrid) and Professor of Pathology at Universidad Complutense (Madrid).

Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at HM Hospitales (Spain) and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York).

He is the 2023 recipient of the Mary J. Matthews Pathology & Transitional Research Award (International Association for the Study of Lung Cancer, IASLC) and the Deputy Chair of the IASLC Pathology Committee.

His main clinical and research expertise is in cancer biomarker testing.

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.